Patents Represented by Attorney, Agent or Law Firm Michael J. Atkins
-
Patent number: 6043407Abstract: A debridement pad is provided having fibrinolysin enzyme, desoxyribonuclease enzyme and cellulosic material in the form of a lyophilized sponge-like pad. Placement of the pad over an open wound produces a gel which has a protective effect and which releases the enzymes directly into the wound. The pad may also contain antibiotic agents.Type: GrantFiled: July 21, 1998Date of Patent: March 28, 2000Assignee: Warner-Lambert CompanyInventors: Shahid Amir Lodhi, Josephine Milstone
-
Patent number: 6028095Abstract: The present invention comprises a method for treating inflammatory bowel disease (IBD) by administering to a mammal in need thereof a therapeutically effective amount of at least one histamine H.sub.3 -receptor agonist. It has been unexpectedly found that H.sub.3 -receptor agonists are effective at alleviating the effects of IBD and, therefore, are useful for treating IBD, including ulcerative colitis and Crohn's disease.Type: GrantFiled: October 11, 1999Date of Patent: February 22, 2000Assignee: Warner-Lambert CompanyInventor: Antonio Guglietta
-
Patent number: 6027746Abstract: The present invention relates to novel liquid oral suspensions incorporated within a soft gelatin capsule comprised of a bitter or bad-tasting pharmaceutical active (such as antihistamines, decongestants and the like) which is dispersed within an adsorbate comprised of magnesium trisilicate, silicon dioxide or mixture thereof. The adsorbate is dispersed within an aqueous or non-aqueous carrier base and combined with other flavors, sweeteners, emulsifiers and the like. The adsorbate not only taste-masks the active but also insures that is evenly dispersed through the liquid suspension so that a uniform dosage rate is readily achievable. The encapsulation of the adsorbate within a gelatin capsule makes administration easier for children andmore convenient. The capsule also affords the adsorbate suspension greater shelf life.Type: GrantFiled: April 22, 1998Date of Patent: February 22, 2000Assignee: Warner-Lambert CompanyInventor: Stanley Lech
-
Patent number: 5981595Abstract: A pharmaceutically useful compound which lowers blood cholesterol levels having the formula ##STR1## wherein X is oxygen or --NH--; Ar is phenyl, substituted phenyl, naphthyl or substituted naphthyl; R.sub.1 is hydrogen, lower alkyl or benzyl; and R.sub.2 is a straight or branched alkyl group having from 5 to 17 carbon atoms which may be substituted on the 1-carbon position with methyl, ethyl, phenyl, or substituted phenyl, or a cycloalkyl group having from 3 to 8 carbon atoms.Type: GrantFiled: July 1, 1993Date of Patent: November 9, 1999Assignee: Warner-Lambert CompanyInventors: Joseph Armand Picard, William Howard Roark, Bruce David Roth
-
Patent number: 5792474Abstract: According to the present invention, there is provided a continuous method for the production of retarded pharmaceutical compositions by an extrusion process. A mixture of an active material, a low and high melting lipid or lipoid components is introduced by means of an extruder screw conveyor into a preheated extruder and brought to a temperature which is at most about 4.degree. C. above the melting temperature of the low melting component at a pressure of about 200 to about 600 kPa(N/m.sup.2). The mass is extruded through a nozzle plate with a nozzle diameter of about 1.2 to about 4 mm and subsequently cooled, and if desired, granulated.Type: GrantFiled: June 16, 1995Date of Patent: August 11, 1998Assignee: Goedecke AktiengesellschaftInventor: Roland Rauchfuss
-
Patent number: 5760050Abstract: 1,2,3,4-Tetrahydro-chromeno?3,4-c!pyridin-5-ones of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.5 include hydrogen, alkyl, alkoxy, hydroxy, halo, nitro, amino, and trifluoromethyl; R.sub.4 is unsubstituted or substituted phenyl, pyridyl, or quinolinyl; and n is 0 to 4, are useful to treat psychosis in mammals, particularly schizophrenia.Type: GrantFiled: February 27, 1997Date of Patent: June 2, 1998Assignee: Warner-Lambert CompanyInventors: David Thomas Connor, Steven Robert Miller, Paul Charles Unangst, Lawrence David Wise
-
Patent number: 5686104Abstract: An oral pharmaceutical composition is provided for treating hypercholestereolemia or hyperlipidemia containing an advantageous formulation for stabilizing the HMG-CoA coenzyme A inhibitor, CI-981 Hemi-Calcium, of formula (IA) ##STR1## with effective amounts of calcium carbonate. A method for preparing a CI-981 stabilizing composition is described.Type: GrantFiled: May 20, 1994Date of Patent: November 11, 1997Assignee: Warner-Lambert CompanyInventors: Nancy Mills, Nouman A. Muhammad, Jay Weiss, Russell U. Nesbitt
-
Patent number: 5681577Abstract: A chewable cold/sinus preparation comprising a bitter tasting mixture of a decongestant such as pseudoephedrine and an antihistamine such as diphenhydramine and/or chlorpheniramine maleate is made with no bitter, metallic taste or unpleasant mouthfeel by adsorbing the active drug mixture using a wet granulation process onto a silicon dioxide carrier which comprises from about 50 to about 85% of total weight of the adsorbate composition. A truly multi-symptom relief formula is prepared through the optional addition of an antitussive such as dextromethorphan hydrobromide and/or an analgesic such as meclofenamic acid, aspirin or ibuprofen. Additional excipients such as flavors, sweeteners, lubricants and bulk fillers are added for better taste, improved mouthfeel and as an aid to the tabletting process.Type: GrantFiled: September 19, 1995Date of Patent: October 28, 1997Assignee: Warner-Lambert CompanyInventors: Stanley Lech, Alexander M. Schobel, John Denick, Jr.
-
Patent number: 5666962Abstract: Disclosed is a non-invasive method of measuring the progress of viral activity in a mammalian herpes labialis episode, the method comprising the step of measuring the temperature of the symptomatic area of the herpes labialis episode during the episode. Also disclosed is a non-invasive method of preventing the clinical effects of a herpes labialis episode, the method comprising the steps of: measuring the temperature of the symptomatic area during the herpes labialis episode; and treating the herpes labialis episode with an effective amount of an antiviral agent sufficient to prevent a herpetic lesion.Type: GrantFiled: April 13, 1995Date of Patent: September 16, 1997Assignee: Warner-Lambert CompanyInventor: Philip-John Lamey
-
Patent number: 5656296Abstract: The present invention pertains to a dual control sustained release drug delivery system which comprises a core and a porous coating layer over the core, wherein the coated core comprises (A) a core comprising in percentages by weight of the core composition (a) a medicament present in an amount from about 60% to about 90%; (b) an edible material having a melting point from about 25.degree. C. to about 100.degree. C. selected from the group consisting of (i) fatty acids having an iodine value from about 1 to about 10, (ii) natural waxes, (iii) synthetic waxes, and (iv) mixtures thereof, present in an amount from about 5% to about 40%; and (B) a porous coating layer over the core comprising in percentages by weight of the coating layer composition (a) a pH-independent water-insoluble polymer present in an amount from about 40% to about 80%; and (b) a water-soluble film forming polymer present in an amount from about 20% to about 60%.Type: GrantFiled: June 7, 1995Date of Patent: August 12, 1997Assignee: Warner-Lambert CompanyInventors: Sadath U. Khan, Phyllis Ying, Russell U. Nesbitt, Mahdi B. Fawzi, Jay Weiss
-
Patent number: 5650174Abstract: A solid composition for peroral therapy of cognition impairment is formulated to stabilize the acid labile drug, CI-979 HCl, by layering a mixture of thereof with a binder on mini-sugar spheres, and finally covering the structure with a protective coating.Type: GrantFiled: March 7, 1995Date of Patent: July 22, 1997Assignee: Warner-Lambert CompanyInventors: Nouman Muhammad, Gary D'Alonzo, Shirley Yang, Jay Weiss
-
Patent number: 5641513Abstract: A method for coating pharmaceutical tablets is disclosed in which polymeric coating ingredients are combined with saccharides in a melt spinning operation to form composite particulates. The particulates are then dispersed in water to form an aqueous polymer coating solution, followed by application to pharmaceutical tablets by such methods as spray coating. The particulates dissolve extremely rapidly in water to form a dispersion of the polymer coating ingredients. Such rapid dissolution allows for increased processing rates and avoids disadvantages of the prior art such as the requirement of high sheer rate mixing for long times.Type: GrantFiled: October 17, 1995Date of Patent: June 24, 1997Assignee: Warner-Lambert CompanyInventors: Stanley Lech, John Denick, Jr.
-
Patent number: 5641536Abstract: A method for coating pharmaceutical tablets is disclosed in which polymeric coating ingredients are combined with saccharides in a melt spinning operation to form composite particulates. The particulates are then dispersed in water to form an aqueous polymer coating solution, followed by application to pharmaceutical tablets by such methods as spray coating. The particulates dissolve extremely rapidly in water to form a dispersion of the polymer coating ingredients. Such rapid dissolution allows for increased processing rates and avoids disadvantages of the prior art such as the requirement of high shear rate mixing for long times.Type: GrantFiled: June 6, 1995Date of Patent: June 24, 1997Assignee: Warner-Lambert CompanyInventors: Stanley Lech, John Denick, Jr.
-
Patent number: 5626878Abstract: A medicament adsorbate containing corn syrup having contained therein from about 10 to about 90% by weight of the adsorbate of a medicament drug a magnesium trisilicate having a surface area of at least 400 m.sup.2 /g and having a structure with multiple interstitial spaces, and having adsorbed therein from about 0.5 to about 30% by weight of the adsorbate of a medicament drug, wherein the medicament drug is an antihistamine. A reduction in the electrostatic forces between adsorbates is experienced due to the particle size of the adsorbate being in the range greater than 40 to about 800 um, most of the adsorbates prepared being a particle size greater than 150 um, which allows for better processing.Type: GrantFiled: January 10, 1995Date of Patent: May 6, 1997Assignee: Warner Lambert CompanyInventors: Felipe Garay, Stanley Lech, Mark Oehling
-
Patent number: 5576022Abstract: The present invention pertains to controlled release tacrine drug delivery systems comprising an immediate release composition and a sustained release composition wherein (1) the immediate release composition comprises in percentages by weight of the immediate release composition: (A) immediate release pellets comprising: (a) nonpareil seeds in an amount from about 25% to about 75%; (b) tacrine in an amount from about 10% to about 80%; and (c) a binding agent in an amount from about 1% to about 10%; and (B) a sealing layer over the immediate release pellets comprising: (a) a sealing agent in an amount up to about 6%, and (b) a first plasticizing agent in an amount up to about 5%; and (2) the sustained release composition comprises in percentages by weight of the sustained release composition; (A) the immediate release composition; and (B) a sustaining layer over the immediate release composition comprising; (a) a water-insoluble polymer in an amount from about 40% to about 90%; (b) a water-soluble polymer inType: GrantFiled: April 12, 1995Date of Patent: November 19, 1996Assignee: Warner Lambert CompanyInventors: S. Shirley Yang, Wayne Boisvert, Nouman A. Muhammad, Jay Weiss
-
Patent number: 5512300Abstract: A method for preparing ibuprofen granulations which exhibit improved stability and resistance to the formation of low melting point eutectics is disclosed. The method includes forging an amalgamation of ibuprofen and an alkali metal in a physical matrix which is suitable for inclusion in a composition without destroying the amalgamation. The stabilized ibuprofen granulation can be combined with other active ingredients and/or excipients to form compositions which have extended shelf life and are resistant to the formation of low melting point eutectics.Type: GrantFiled: September 15, 1992Date of Patent: April 30, 1996Assignee: Warner-Lambert CompanyInventors: Timothy H. Weng, Michael G. Williams
-
Patent number: 5504073Abstract: Certain compounds have been synthesized and found to be effective inhibitors of phospholipase A.sub.2 (PLA.sub.2), and thereby useful in the treatment of intestinal cholesterol absorption and the disease states arising therefrom, such as hypercholesterolemia and coronary artery disease.Type: GrantFiled: July 1, 1994Date of Patent: April 2, 1996Assignee: Warner-Lambert CompanyInventor: Reynold Homan
-
Patent number: D377085Type: GrantFiled: July 28, 1995Date of Patent: December 31, 1996Assignee: Warner-Lambert CompanyInventor: George E. Tortarolo
-
Patent number: D377086Type: GrantFiled: July 28, 1995Date of Patent: December 31, 1996Assignee: Warner-Lambert CompanyInventor: George E. Tortarolo
-
Patent number: D383549Type: GrantFiled: April 1, 1996Date of Patent: September 9, 1997Assignee: Warner-Lambert CompanyInventors: Marylou Arnett, Dorothy A. Robinson